Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: Ultragenyx Pharmaceutical Inc. is facing a securities class action lawsuit due to allegations of failing to disclose material information. The case relates to a significant drop in share price following the announcement that phase 3 studies for its drug setrusumab did not meet efficacy endpoints. Investors have until April 6, 2026, to file lead plaintiff applications as part of this legal action. The lawsuit highlights broader concerns regarding Ultragenyx's management and operational evaluations following the study results.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors have incurred significant losses due to a sharp drop in share price.
  • The company failed to achieve positive results in critical Phase III studies.
  • There are ongoing legal actions that could further impact the company's reputation and financial standing.

Full Press Release Details

NEW ORLEANS, March 18, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

The deadline is April 6, 2026.

What is the Class Period for the Ultragenyx case?

The Class Period is from August 3, 2023, to December 26, 2025.

What caused Ultragenyx's share price to drop?

The drop was due to failed Phase III studies for setrusumab.

Who can investors contact for legal options?

Investors can contact Kahn Swick & Foti, LLC at 844-367-9658.

What is ClaimsFiler's purpose?

ClaimsFiler helps investors recover from securities class action settlements.

Last updated: Mar 19, 2026